Following completion of this course the learner will be able to:
- Recognize the basic anatomy and physiology of the Nervous System
- Describe Nervous System Receptor Pharmacology
- Prepare for challenges of developing efficacious yet safe compounds by identifying common CNS and PNS diseases
- Recognize the regulatory concerns for drug abuse of novel compounds.
- Evaluate the new concerns and potential models to assess suicidality as well as peripheral neuropathy.
Kristy D. Bruse, PhD, (Consultant)
Dr. Kristy D. Bruse is a CardioRespiratory Disease Model (especially Pulmonary Artery Hypertension rat models) and Safety Pharmacology Expert Consultant. She has been involved in industry, academia and veterinary medicine for over three decades. Dr. Bruse has a strong belief that Safety Pharmacology is an integral component in the drug development process. Better identification of lead compounds and quality safety assessment will only increase the success rate for biotech and pharmaceutical companies as well as provide safe and effective drugs for patients. She has been an active member of the Safety Pharmacology Society since 2001 and was the 2008 Vice President-elect, 2009 Vice President and the 2010 President. Dr. Bruse can provide Assist in Discovery and Early Safety Assessment to streamline the drug discovery process.
Matthew Abernathy, PhD, (Eli Lilly)
Dr. Abernathy earned a BS in biology at Indiana University and a PhD in biological sciences at Western Michigan University. His research interest is to characterize the safety and/or efficacy of new drug candidates for use in otic or systemically administered formulations. He has a broad background in applied biology, having worked in various positions in contract research laboratories for the past nine years. He began as a research technician at MPI Research collecting data to evaluate potential off-target/adverse drug effects on the cardiovascular, respiratory, and central nervous systems in preclinical laboratory animal models. From there he transitioned to a surgical technician role at the Borgess Medical Device Research Laboratory where he worked with a team of Cardiovascular Interventionists to evaluate safety aspects of new stent prototypes, including incidence of stroke and restenosis. He returned to MPI Research to lead preclinical drug screening efforts.